Soo-Hyun Kim

Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor.

J. Turnbull, S. Guimond, Soo-Hyun Kim, 2011, The Journal of endocrinology.

IL-32, a proinflammatory cytokine in rheumatoid arthritis.

Do-Young Yoon, Pilar Barrera, L. Joosten, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Regulation of myeloid leukemia by the cell fate determinant Musashi

Takahiro Ito, Bryan Zimdahl, Tannishtha Reya, 2010, Nature.

Anti-tumor activity of noble indirubin derivatives in human solid tumor models In Vitro

Soo-Jeong Choi, Yong‐Chul Kim, H. Kuh, 2009, Archives of pharmacal research.

A Study of Legibility by Monitor Letter Color with an Eye Tracker

Tae-Hong Kim, Young-Gil Kim, Jae-Myoung Seo, 2014 .

The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation.

S. Kim, Daniela Novick, Menachem Rubinstein, 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Proteinase 3 is an IL-32 binding protein.

Aharon Rabinkov, C. Dinarello, Soohyun Kim, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

Giuseppe Saglio, G. Saglio, Dong-Wook Kim, 2011, Leukemia & lymphoma.

E7‐expressing HaCaT keratinocyte cells are resistant to oxidative stress‐induced cell death via the induction of catalase

Do-Young Yoon, Kyung-Joo Cho, Jung-Hyun Shim, 2005, Proteomics.

Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator.

Youli Hu, P. Bouloux, Soo-Hyun Kim, 2004, The Biochemical journal.